Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Frank M. Horling"'
Autor:
Alexandra Kopic, Tanja Ruthsatz, Hanspeter Rottensteiner, Frank M. Horling, Friedrich Scheiflinger, Werner Höllriegl, Alexander Bauer, Gerald Schrenk, Peter Leidenmühler, Martin J. Wolfsegger, Gerald Höbarth, Alfred Weber, Herbert Gritsch, Birgit M. Reipert, Helmut Glantschnig, Karima Benamara, Veronika Ehrlich, Michael Dockal, Maria Schuster, Peter Turecek
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:95-105
Extended half-life (EHL) factor therapies are needed to reduce the burden of prophylaxis and improve treatment adherence in patients with hemophilia. BAX 826 is a novel polysialylated full-length recombinant factor VIII [polysialyic acid (PSA) rFVIII
Autor:
Damir Fetahagic, Friedrich Scheiflinger, Bettina Hartlieb, Anita Kruzik, Maurus de la Rosa, Birgit M. Reipert, Herwig Koppensteiner, Frank M. Horling, Sebastian Dorn
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Preexisting immunity against adeno-associated virus (AAV) is a major challenge facing AAV gene therapy, resulting in the exclusion of patients from clinical trials. Accordingly, proper assessment of anti-AAV immunity is necessary for understanding cl
Autor:
Maurus de la Rosa, Stefan Romeder-Finger, Sogue Coulibaly, Sebastian Dorn, Frank M. Horling, Alfred Weber, Herwig Koppensteiner, Bettina Hartlieb, Birgit M. Reipert, Anita Kruzik, Friedrich Scheiflinger, Werner Hoellriegl, Damir Fetahagic
Publikováno v:
Human Gene Therapy Methods. 30:35-43
Patients with preexisting anti-adeno-associated virus serotype 8 (AAV8) neutralizing antibodies (NAbs) are currently excluded from AAV8 gene therapy trials. Therefore, the assessment of biologically relevant AAV8-NAb titers is critical for product de
Publikováno v:
Haemophilia. 25
Autor:
Anita, Kruzik, Herwig, Koppensteiner, Damir, Fetahagic, Bettina, Hartlieb, Sebastian, Dorn, Stefan, Romeder-Finger, Sogue, Coulibaly, Alfred, Weber, Werner, Hoellriegl, Frank M, Horling, Friedrich, Scheiflinger, Birgit M, Reipert, Maurus, de la Rosa
Publikováno v:
Human gene therapy methods. 30(2)
Patients with preexisting anti-adeno-associated virus serotype 8 (AAV8) neutralizing antibodies (NAbs) are currently excluded from AAV8 gene therapy trials. Therefore, the assessment of biologically relevant AAV8-NAb titers is critical for product de
Autor:
Srilatha D Tangada, Eva-Maria Muchitsch, Gerald Schrenk, Borislava G. Pavlova, Werner Höllriegl, Frank M. Horling, Peter Turecek, Artur Mitterer, Hanspeter Rottensteiner, Brigitt Abbühl, Herbert Gritsch, Barbara Dietrich, Alexandra Schiviz, Birgit M. Reipert, Miranda Chapman, Friedrich Scheiflinger
Publikováno v:
Expert Review of Clinical Pharmacology. 8:163-177
Nonacog gamma is a new recombinant factor IX to treat factor IX deficiency. It is indicated for control of bleeding episodes, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and child
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 128
Detecting and characterizing of anti-drug antibodies (ADA) against a protein therapeutic are crucially important to monitor the unwanted immune response. Usually a multi-tiered approach that initially rapidly screens for positive samples that are sub
Autor:
Alexander Bauer, Johannes Oldenburg, Christian Lubich, Birgit M. Reipert, Friedrich Scheiflinger, Frank M. Horling, Jürgen Siekmann, Thomas Prenninger, Maurus de la Rosa, Peter Allacher
Publikováno v:
Pharmaceutical research. 33(9)
Recent findings demonstrated anti-PEG antibody formation in some healthy individuals and patients who have not received PEGylated biotherapeutics. Some of these findings evoked criticism because of shortcomings in the antibody assays used. To better
Autor:
Friedrich Scheiflinger, Shawn F. J. Whelan, Christoph J. Hofbauer, Paul Knöbl, Gerald Schrenk, Jerzy Windyga, Andreas Greinacher, Birgit M. Reipert, Christoph Male, Jadranka Koehn, John-Philip Lawo, Andreas Tiede, Frank M. Horling, Maria Hirschler, Johannes Oldenburg, Peter Allacher
Publikováno v:
Blood. 125(7)
Recently, we reported that distinct immunoglobulin (Ig) isotypes and IgG subclasses of factor VIII (FVIII)-specific antibodies are found in different cohorts of patients with hemophilia A and in healthy individuals. Prompted by these findings, we fur
Autor:
Frank M. Horling, Friedrich Scheiflinger, Peter Turecek, Eva-Maria Muchitsch, Alexandra Schiviz, Karima Benamara, Hans Peter Schwarz, Barbara Dietrich, Hanspeter Rottensteiner, Werner Hoellriegl
Publikováno v:
International Journal of Hematology
Baxter has developed a new recombinant factor IX (rFIX) drug product (BAX326) for treating patients with hemophilia B, or congenital FIX deficiency. An extensive preclinical program evaluated the pharmacokinetics, efficacy, and safety of BAX326 in di